Article Text

PDF
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
  1. R Noecker
  1. Correspondence to: R Noecker UPMC Eye Center, Eye and Ear Institute, University of Pittsburgh School of Medicine, 203 Lothrop Street, Suite 820, Pittsburgh, PA 15213, USA;noeckerrj{at}upmc.edu

Statistics from Altmetric.com

The efficacy of bimatoprost and travoprost in patients with glaucoma and ocular hypertension

Dr Cantor’s article1 (see page 1370)on the efficacy of bimatoprost and travoprost in patients with glaucoma and ocular hypertension shows again that both these drugs are efficacious in lowering intraocular pressure (IOP). The study is a prospective, randomised investigator-blinded trial, which has results similar to those found in studies carried out with the drugs in this class.

Dr Cantor found that bimatoprost lowered IOP slightly more than travoprost in this study population. This is the first relatively large two-arm study to show this in a head-to-head design. The current study supports others who have shown that bimatoprost is somewhat more efficacious than travoprost.

What is reassuring about this study is that there are no surprises, and the results appear to be consistent with what has been seen in the collection of other studies comparing drugs in this class. The relative degrees of IOP reduction, rates of hyperaemia and clinical success parameters are within the range …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles